Oncology

Back to articles

Ibrutinib: A single-agent oral therapy for some lymphomas, leukemias

KEY POINT

Treatment of relapsed/refractory mantle cell lymphoma (MCL) with ibrutinib (Imbruvica—Pharmacyclics) was associated with a response rate of 68%; prior treatment with bortezomib (Velcade—Millennium, Takeda) had no effect on response rate. Study results led to accelerated FDA approval of ibrutinib in November 2013, with subsequent expanded approval in February 2014.

SOURCES

Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.

Zucca E et al. Toward new treatments for mantle-cell lymphoma [editorial]? N Engl J Med. 2013;369:571–572.